N-Acetyl Semax Amidate

Semax: Met-Glu-His-Phe-Pro-Gly-Pro; heptapeptide; MW approximately 808 Da. The first four amino acids (Met-Glu-His-Phe) constitute ACTH(4-7) — the melanocortin-active core fragment of ACTH that retains receptor binding and neuroprotective properties without the adrenal steroidogenic activity of full-length ACTH. The C-terminal Pro-Gly-Pro tripeptide extension was added by the Russian research team to: (1) stabilize the ACTH(4-7) core against exopeptidase cleavage from the C-terminus; (2) provide the structural motif that enables effective intranasal transport across the olfactory epithelium to the CNS; and (3) contribute independent pharmacological activity through its own signaling in brain tissue. The Pro-Gly-Pro fragment is not merely a stability enhancer — Inozemtseva et al. (2024) demonstrated that Pro-Gly-Pro alone produces antidepressant-like and antistress effects in rodent models, suggesting it contributes independently to Semax's behavioral effects.

BDNF upregulation: the most consistently documented Semax mechanism. Dolotov et al. (2006, Brain Research) demonstrated rapid BDNF induction in rat hippocampus after intranasal Semax; subsequent studies in cerebral ischemia and intact animals have replicated this finding across models. BDNF drives synaptic plasticity, neuronal survival, and long-term potentiation — the cellular basis of learning and memory. Melanocortin receptor modulation: Semax's ACTH(4-7) core binds melanocortin receptors, particularly MC4R, which regulates attention, learning, and memory in the CNS independently of its role in appetite and sexual function at other receptor populations. Unlike full-length ACTH, ACTH(4-7) does not stimulate adrenal cortisol production at therapeutic doses. Dopaminergic and serotonergic effects: Semax enhances dopamine and serotonin turnover in multiple brain regions; these monoamine effects contribute to its focus and mood-elevating properties. Neuroprotection in ischemia: multiple rodent models show reduced infarct volume, improved neurological scores, and BDNF/TrkB upregulation in ischemic stroke — the primary evidence base for its Russian clinical approval.

Russian regulatory approval (ischemic stroke; cognitive impairment) is based on clinical studies. The most cited accessible evidence: Gusev E.I., Martynov M.Y., et al. (2018, Zhurnal Nevrologii i Psikhiatrii): n=110 patients; non-randomized clinical trial; stroke rehabilitation; Semax 6,000 mcg/day intranasally in two 10-day courses separated by a 20-day interval; plasma BDNF elevated; Barthel index (daily function) and MRC motor-scale scores improved vs comparator subgroups not receiving Semax; both early-rehabilitation (89 days post-stroke) and late-rehabilitation (214 days post-stroke) subgroups showed benefit; published in Russian-language journal. Grade B (limited human; non-randomized; Russian-language publication; single institution). For the cognitive enhancement application (not stroke), human evidence is primarily from open-label post-registration observations and community experience.

Peptides with free N-terminal amino groups (H₂N-) are vulnerable to aminopeptidases — enzymes that sequentially cleave amino acids from the N-terminus. Plasma aminopeptidases, particularly leucine aminopeptidase, are a primary degradation mechanism for therapeutic peptides in the bloodstream. N-acetylation replaces the free amino group with an acetamide (CH₃CO-NH-), which aminopeptidases cannot recognize as a substrate. The acetyl group is chemically inert to the enzyme's active site geometry. This single modification can extend a peptide's plasma half-life by a factor of 2-10x depending on the peptide, because N-terminal aminopeptidase cleavage is often the rate-limiting degradation step. The acetyl group also increases the compound's lipophilicity slightly — replacing a charged NH₂ with an uncharged acetamide — which improves passive diffusion across lipid bilayers including the blood-brain barrier.

Peptides with free C-terminal carboxyl groups (-COOH) are vulnerable to carboxypeptidases, which cleave amino acids from the C-terminus. C-terminal amidation replaces the carboxyl with an amide (-CONH₂), blocking carboxypeptidase recognition. This extends half-life from the C-terminal direction, complementing N-acetylation's N-terminal protection. The amide modification has an additional pharmacological consequence beyond stability: it neutralizes the negative charge of the C-terminal carboxyl group. Many neuropeptide receptor binding pockets have evolved to interact with the C-terminal region of their natural peptide ligands. In a significant proportion of neuropeptide-receptor interactions, the C-terminal amide produces better receptor fit than the free carboxyl — in some cases substantially improving binding affinity. For Semax, where the C-terminal proline's carboxyl group is the last point of receptor interaction, amidation may improve GLP-Pro-Pro's receptor complementarity with melanocortin and other receptor subtypes.

N-acetylation protects the N-terminus; C-terminal amidation protects the C-terminus. Together they create a peptide with no enzymatic attack points at either end — the only remaining degradation pathways are mid-chain endopeptidases, which are generally slower and less efficient than the terminal exopeptidases. The result: a compound estimated to be approximately 3-4x more potent per microgram than unmodified Semax in community experience, consistent with substantially extended stability and possibly improved receptor interaction from the amide terminus. The potency enhancement is community-empirical — no controlled pharmacokinetic study has compared NA Semax Amidate to Semax head-to-head in humans or animals. The 3-4x estimate reflects community dosing convergence: users who have used both forms consistently report that roughly 1/3 to 1/4 the dose of NA Semax Amidate achieves comparable subjective effects to standard Semax.

Modification

What It Blocks

Chemical Change

Effect on Stability

Effect on Receptor

Effect on BBB

N-terminal acetylation

Aminopeptidase (N-terminal exopeptidase)

H₂N- → CH₃CO-NH-

2-10x longer half-life from N-terminal direction

Neutral N-terminus (minor effect on binding)

Increased lipophilicity → improved passive BBB diffusion

C-terminal amidation

Carboxypeptidase (C-terminal exopeptidase)

--COOH → --CONH₂

Significant extension from C-terminal direction

Neutral C-terminus often improves receptor fit; better complementarity to binding pocket geometry

Minor lipophilicity increase

Both combined

Both N- and C-terminal exopeptidases

Ac-...--NH₂

Maximum enzymatic protection; mid-chain endopeptidase only remaining pathway

Additive improvements at both receptor termini

Combined lipophilicity increase → best BBB penetration of the series

Intranasal is the primary route for both Semax and NA Semax Amidate, following the same olfactory epithelium to CNS transport mechanism established for Semax in Russian clinical practice. The nasal route provides direct access to the CNS via the olfactory nerve pathway, bypassing the systemic circulation and circumventing concerns about peripheral stability (though the modified form is stable systemically as well). Limitless spray: 0.1% solution (1 mg/mL); approximately 50-100 mcg per drop; 2-3 drops per nostril for most community doses. The 1% solution (10 mg/mL) is used for higher dose protocols in the tradition of Russian stroke recovery (1,000 mcg+ per drop), available from some vendors.

Protocol

Dose

Route

Notes

Low / first use

100-200 mcg/day

Intranasal (0.1% spray)

2-4 drops/nostril at 50 mcg/drop; assess 1 week before adjusting

Standard community

200-400 mcg/day

Intranasal

Most common community effective range for cognitive enhancement; split AM and early afternoon

Higher cognitive

400-600 mcg/day

Intranasal

Upper end for experienced users; risk of overstimulation increases

Semax-equivalent equivalent to 600-1200 mcg Semax

200-400 mcg NA Semax Amidate

Intranasal

Using 3x potency estimate; NA Semax Amidate community doses approximately 1/3 of Semax doses

Cycle

4-6 weeks on; 2-3 weeks off

N/A

Prevents receptor downregulation; consistent with Russian Semax course protocols

NA Semax Amidate's stimulatory properties (dopaminergic and serotonergic enhancement, melanocortin receptor activation) produce a psychostimulant-adjacent effect profile that interferes with sleep if dosed in the afternoon or evening. Community consensus and Semax clinical guidance align: dose in the morning only, or at most morning and early afternoon (no later than 2 PM). Effects onset within 20-40 minutes of intranasal administration; peak at 1-2 hours; the modified form likely has longer duration than standard Semax due to stability enhancements, potentially 6-8+ hours vs 4-6 hours for Semax. Evening dosing commonly produces insomnia.

Community reports for NA Semax Amidate are consistent across independent sources: enhanced focus and sustained attention (onset 20-40 min); improved information processing and verbal fluency; reduced mental fatigue during cognitively demanding tasks; sometimes described as 'a sharper version of the signal' relative to standard Semax. The stimulatory quality is more pronounced than Selank or Noopept — consistent with its dopaminergic mechanism. It does not produce the anxiolytic quality of Selank or the sedative calming of other nootropic peptides. Users seeking anxiety reduction alongside cognitive enhancement often stack NA Semax Amidate with Selank or NA Selank Amidate (Adamax).

NA Semax Amidate produces mild psychostimulant-adjacent effects at community doses — not amphetamine-like, but more activating than Noopept or Selank. Community reports: mood lift and motivation increase; mild euphoria in some users at higher doses (grade E); irritability and overstimulation if dosed too high or too frequently. The dopaminergic component is the most likely driver. At standard doses (200-400 mcg/day), the stimulatory effect is generally described as facilitating and functional rather than uncomfortable. At higher doses (600+ mcg/day), some users report jaw clenching, anxiety, and mental overstimulation — consistent with dopaminergic excess.

Tolerance development with prolonged continuous use is community-documented. The mechanism likely involves melanocortin receptor downregulation and monoamine system adaptation. Community consensus: cycle 4-6 weeks on, 2-3 weeks off minimum. Cycling also follows the precedent of Russian Semax clinical protocols (10-day courses with rest periods). Continuous use without cycling is associated with diminishing effects and, in some reports, rebound fatigue after stopping. This is behavioral adaptation, not dependence — no withdrawal syndrome is documented.

NA Semax Amidate has no independent human safety data. Safety assessment is inferred from Semax's clinical record. Semax safety: no serious adverse events reported in Russian clinical trials up to 12,000 mcg/day for stroke applications; no hepatotoxicity; no cardiotoxicity; no addiction potential identified; no documented withdrawal syndrome. Mild adverse effects in the community: headache (higher doses); irritability and anxiety (overstimulation); insomnia (late dosing). The modifications in NA Semax Amidate do not introduce new pharmacophores or functional groups with known toxicity concerns — acetyl and amide groups are biochemically inert and present in endogenous compounds throughout the body.

The 3-4x potency increase per microgram means that dose errors that would be minor with standard Semax become more significant with NA Semax Amidate. Nasal spray drops vary in size — the volume of a single drop from a spray bottle can vary 20-50% depending on the angle, pressure, and formulation. At 0.1% solution with variable drop size, users are working in the 50-150 mcg range per drop rather than a precise amount. This imprecision matters more when the compound is 3-4x more potent than the reference. Community guidance: start at 1-2 drops per nostril and assess carefully before increasing.

These are different compounds from different parent peptides with different mechanisms and different effects. Semax = ACTH-derived; melanocortin receptor; BDNF; cognitive stimulation. Selank = tuftsin analog; GABA-A modulation; anxiolytic; stress reduction. Their NA-amidate versions share the naming convention and the dual modification chemistry, but the underlying pharmacology is completely different. Confusing them is one of the most common sourcing errors in this market segment.

NA Semax Amidate is not approved by any regulatory body anywhere. Russian approval for Semax is based on trials for unmodified Met-Glu-His-Phe-Pro-Gly-Pro. The chemical modifications produce a distinct molecular entity that has not been independently studied in humans or animals in peer-reviewed published literature. Russian approval for the parent compound does not extend to derivatives. This is research chemical territory.

Higher potency per microgram means the therapeutic window shifts and dose precision becomes more important — not that safety concerns are eliminated. If NA Semax Amidate is 3-4x more potent, then 400 mcg NA Semax Amidate is pharmacologically equivalent to 1,200-1,600 mcg Semax. At these equivalent doses in Semax terms, the overstimulation effects (anxiety, irritability, insomnia) are reliably documented. Start low; titrate slowly.

• Choose NA Semax Amidate for: cognitive stimulation, focus, BDNF-mediated neuroplasticity, sustained attention during cognitively demanding periods.
• Dose: start 100-200 mcg/day intranasal; titrate to 200-400 mcg/day; do not exceed 600 mcg/day; note this is approximately 1/3 the equivalent Semax dose.
• Timing: morning only; no later than 2 PM; evening dosing causes insomnia.
• Cycle: 4-6 weeks on; 2-3 weeks off; prevents receptor adaptation.
• Stack with Selank/Adamax: if anxiety component or stress reduction is also needed; the two compounds are complementary (cognitive stimulation + anxiolysis) with different mechanisms.
• The naming check: verify vendor supplies Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH₂ (NA Semax Amidate), not Ac-Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH₂ (NA Selank Amidate/Adamax). CAS 2920938-90-3 vs the Selank-based compound. These are not interchangeable.

— End of N-Acetyl Semax Amidate —

THE PEPTIDE BIBLE | N-Acetyl Semax Amidate | For Research & Educational Purposes Only